Arnonk Karni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5088986/publications.pdf

Version: 2024-02-01

61	3,177	304368	155451
papers	citations	22 h-index	55 g-index

61	61	61	4329
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 209-220.	13.9	1,324
2	Increased T cell reactivity to amyloid Î² protein in older humans and patients with Alzheimer disease. Journal of Clinical Investigation, 2003, 112, 415-422.	3.9	173
3	Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetate. Journal of Neuroimmunology, 2005, 167, 215-218.	1.1	165
4	Innate Immunity in Multiple Sclerosis: Myeloid Dendritic Cells in Secondary Progressive Multiple Sclerosis Are Activated and Drive a Proinflammatory Immune Response. Journal of Immunology, 2006, 177, 4196-4202.	0.4	148
5	Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. Journal of Neuroimmunology, 2008, 195, 186-193.	1.1	106
6	Elevated Levels of Antibody to Myelin Oligodendrocyte Glycoprotein Is Not Specific for Patients With Multiple Sclerosis. Archives of Neurology, 1999, 56, 311.	4.9	94
7	IL-18 is linked to raised IFN-Î³ in multiple sclerosis and is induced by activated CD4+ T cells via CD40â€“CD40 ligand interactions. Journal of Neuroimmunology, 2002, 125, 134-140.	1.1	82
8	Association of MS with thyroid disorders. Neurology, 1999, 53, 883-883.	1.5	73
9	Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. Journal of Neuroimmunology, 2005, 163, 157-164.	1.1	71
10	HLA Class II Susceptibility to Multiple Sclerosis Among Ashkenazi and Non-Ashkenazi Jews. Archives of Neurology, 1999, 56, 555.	4.9	70
11	PD-1 ligands, negative regulators for activation of naÃ¯ve, memory, and recently activated human CD4+ T cells. Cellular Immunology, 2004, 230, 89-98.	1.4	64
12	Serum anti-Glc(Î±1,4)Glc(Î±) antibodies as a biomarker for relapsingâ€“remitting multiple sclerosis. Journal of the Neurological Sciences, 2006, 244, 59-68.	0.3	58
13	Central Nervous System Manifestation of IgG4-Related Disease. JAMA Neurology, 2014, 71, 767.	4.5	51
14	A wearable sensor identifies alterations in community ambulation in multiple sclerosis: contributors to real-world gait quality and physical activity. Journal of Neurology, 2020, 267, 1912-1921.	1.8	46
15	Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-Î³ production of CD8+ T cells in secondary progressive multiple sclerosis. Journal of Neuroimmunology, 2004, 146, 189-198.	1.1	45
16	In vitro induction of regulatory T cells by anti-CD3 antibody in humans. Journal of Autoimmunity, 2008, 30, 21-28.	3.0	45
17	Interferon-Î² therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism. Journal of Neuroimmunology, 2009, 211, 114-119.	1.1	38
18	The Frequency of Multiple Sclerosis in Jewish and Arab Populations in Greater Jerusalem. Neuroepidemiology, 2003, 22, 82-86.	1.1	37

#	Article	IF	Citations
19	Role of Immunosuppressive Therapy for the Treatment of Multiple Sclerosis. Neurotherapeutics, 2013, 10, 77-88.	2.1	36
20	Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses. Frontiers in Immunology, 2022, 13, 868915.	2.2	32
21	Increased anti-KIR4.1 antibodies in multiple sclerosis: Could it be a marker of disease relapse?. Multiple Sclerosis Journal, 2015, 21, 572-579.	1.4	29
22	Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel. Journal of Neuroimmunology, 2016, 293, 65-70.	1.1	28
23	The place of the botulinum toxin in the management of multiple sclerosis. Clinical Neurology and Neurosurgery, 2010, 112, 592-596.	0.6	27
24	Safety of influenza and H1N1 vaccinations in patients with myasthenia gravis, and patient compliance. Muscle and Nerve, 2011, 43, 893-894.	1.0	23
25	Seasonal and H1N1v influenza vaccines in MS: Safety and compliance. Journal of the Neurological Sciences, 2012, 314, 102-103.	0.3	21
26	Elevated and dysregulated bone morphogenic proteins in immune cells of patients with relapsingâ€“remitting multiple sclerosis. Journal of Neuroimmunology, 2013, 264, 91-99.	1.1	20
27	Multiple sclerosis is associated with psoriasis. A caseâ€“control study. Journal of the Neurological Sciences, 2014, 338, 226-228.	0.3	20
28	Reduced production of noggin by immune cells of patients with relapsingâ€“remitting multiple sclerosis. Journal of Neuroimmunology, 2011, 232, 171-178.	1.1	18
29	Dysregulated neurotrophin mRNA production by immune cells of patients with relapsing remitting multiple sclerosis. Journal of the Neurological Sciences, 2010, 295, 31-37.	0.3	17
30	Early post-marketing experience with edaravone in an unselected group of patients with ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 260-263.	1.1	17
31	Nightly Sublingual Tizanidine HCl in Multiple Sclerosis. Clinical Neuropharmacology, 2010, 33, 151-154.	0.2	15
32	Low and dysregulated production of follistatin in immune cells of relapsingâ€“remitting multiple sclerosis patients. Journal of Neuroimmunology, 2011, 238, 96-103.	1.1	15
33	High serum levels of BMP-2 correlate with BMP-4 and BMP-5 levels and induce reduced neuronal phenotype in patients with relapsing-remitting multiple sclerosis. Journal of Neuroimmunology, 2017, 310, 120-128.	1.1	14
34	Reduced ErbB4 Expression in Immune Cells of Patients with Relapsing Remitting Multiple Sclerosis. Multiple Sclerosis International, 2011, 2011, 1-7.	0.4	13
35	Can Treatment With Nonsteroidal Anti-inflammatory Drugs Protect From Dementia?. Archives of Neurology, 2009, 66, 538.	4.9	11
36	Treatment with Anti-EGF Ab Ameliorates Experimental Autoimmune EncephalomyelitisviaInduction of Neurogenesis and Oligodendrogenesis. Multiple Sclerosis International, 2014, 2014, 1-9.	0.4	11

#	Article	IF	Citations
37	Characterization of patients with ocular myasthenia gravis â€" A case series. ENeurologicalSci, 2016, 4, 30-33.	0.5	11
38	Development of Novel Promiscuous Anti-Chemokine Peptibodies for Treating Autoimmunity and Inflammation. Frontiers in Immunology, 2017, 8, 1432.	2.2	10
39	Leukoaraiosis is associated with arterial wall thickness: A quantitative analysis. Neuropathology, 2012, 32, 227-233.	0.7	8
40	Teaching Neuro Images : Hypertrophic olivary degeneration in a young man with POLG gene mutation. Neurology, 2015, 84, e59.	1.5	7
41	Dysregulated production of leukemia inhibitory factor in immune cells of relapsing remitting multiple sclerosis patients. Journal of Neuroimmunology, 2015, 278, 85-89.	1.1	7
42	A tri-modal distribution of age-of-onset in female patients with myasthenia gravis is associated with the gender-related clinical differences. International Journal of Neuroscience, 2019, 129, 313-319.	0.8	7
43	Increased neutralization capacity of TNF-Î± in sera of relapsing remitting multiple sclerosis patients is not related to soluble TNF-Î± receptors or anti-TNF-Î± autoantibody levels. Journal of Neuroimmunology, 2015, 286, 83-85.	1.1	6
44	Natural and induced immunization against CCL20 ameliorate experimental autoimmune encephalitis and may confer protection against multiple sclerosis. Clinical Immunology, 2017, 183, 316-324.	1.4	6
45	Fingolimod Increases Brain-Derived Neurotrophic Factor Level Secretion from Circulating T Cells of Patients with Multiple Sclerosis. CNS Drugs, 2019, 33, 1229-1237.	2.7	6
46	Frailty and Falls in People Living With Multiple Sclerosis. Archives of Physical Medicine and Rehabilitation, 2022, 103, 952-957.	0.5	6
47	High and dysregulated secretion of epidermal growth factor from immune cells of patients with relapsing-remitting multiple sclerosis. Journal of Neuroimmunology, 2013, 257, 82-89.	1.1	5
48	Thymus involvement in myasthenia gravis: Epidemiological and clinical impacts of different self-tolerance breakdown mechanisms. Journal of Neuroimmunology, 2016, 298, 58-62.	1.1	5
49	High Îº free light chain is a potential biomarker for double seronegative and ocular myasthenia gravis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	5
50	Specific Blockade of Bone Morphogenetic Protein-2/4 Induces Oligodendrogenesis and Remyelination in Demyelinating Disorders. Neurotherapeutics, 2021, 18, 1798-1814.	2.1	5
51	Effect of ethnic origin and gender on the clinical manifestations of myasthenia gravis among the Jewish population in Israel. Journal of Neuroimmunology, 2017, 307, 47-52.	1.1	4
52	Erdheim-Chester disease presenting with chorea and mimicking IgG4-related disorder. Neurology: Clinical Practice, 2019, 9, 524-526.	0.8	4
53	Increased Expression of Ephrins on Immune Cells of Patients with Relapsing Remitting Multiple Sclerosis Affects Oligodendrocyte Differentiation. International Journal of Molecular Sciences, 2021, 22, 2182.	1.8	4
54	Differential screening-selected gene aberrative in neuroblastoma (DAN) is increased in the CSF of patients with MS and may be induced by therapy with interferon-Î². Journal of Neuroimmunology, 2016, 292, 93-96.	1.1	3

#	Article	IF	Citations
55	Reduced levels of Coco in sera of multiple sclerosis patients: A potential role in neuro-regeneration failure. Journal of Neuroimmunology, 2019, 327, 36-40.	1.1	3
56	Susacâ€™s syndrome â€“ A new ocular finding and disease outcome. Eye, 2022, 36, 781-788.	1.1	2
57	Vestibular function assessment of Susac syndrome patients by the video head impulse test and cervical vestibular-evoked myogenic potentials. Journal of Vestibular Research: Equilibrium and Orientation, 2020, 30, 393-399.	0.8	2
58	The Role of Molecular Imaging as a Marker of Remyelination and Repair in Multiple Sclerosis. International Journal of Molecular Sciences, 2022, 23, 474.	1.8	2
59	Intractable vomiting and the medulla: neuromyelitis optica spectrum disorder presenting as area postrema syndrome. Postgraduate Medical Journal, 2018, 94, 724-724.	0.9	1
60	Differences in MS clinical and epidemiological characteristics between Ashkenazi and non-Ashkenazi Jewish patients in Israel: a retrospective single center study. Scientific Reports, 2022, 12, 4555.	1.6	1
61	Vestibular function assessment of Susac syndrome patients by the video head impulse test and cervical vestibular-evoked myogenic potentials. Journal of Vestibular Research: Equilibrium and Orientation, 2020, , 1-7.	0.8	0